SCHEMBL466296

SCHEMBL466296

NC(=O)c1cccc(C(N)=O)c1C(N)=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.54
ALDH1A1 P00352 2/20 0.54
MAPT P10636 2/20 0.54
TSHR P16473 2/20 0.54
HSD17B10 Q99714 2/20 0.54
HPGD P15428 1/20 0.54
METAP2 P50579 1/20 0.50
GAA P10253 1/20 0.48
BCAT2 O15382 1/20 0.48
PARP1 P09874 6/20 0.47
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47
PDPK1 O15530 1/20 0.47
AURKA O14965 2/20 0.44
PLK4 O00444 1/20 0.44
CHEK1 O14757 1/20 0.44
DAPK3 O43293 1/20 0.44
MAP4K4 O95819 1/20 0.44
CSF1R P07333 1/20 0.44
RET P07949 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6066755 0.93 KDM4E (0.48) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL7093585 0.91 ALDH1A1 (0.50) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL402013 0.90 BCAT2 (0.56) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL11218560 0.89 ALDH1A1 (0.50) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL11215370 0.89 ALDH1A1 (0.45) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL1512043 0.85 MMP2 (0.47) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL698805 0.85 KDM4E (0.64) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL2411340 0.84 ALDH1A1 (0.55) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL8844181 0.84 ALDH1A1 (0.50) KDM4EALDH1A1MAPTTSHRHSD17B10
SCHEMBL5608858 0.84 BCAT2 (0.61) KDM4EALDH1A1MAPTTSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534627-B2 Polymer particles and related additive manufacturing methods XEROX CORPORATION (US) 2026-01-27 US claimed
US-20250206932-A1 LIVING HINGE OF AN ALPHA-NUCLEATED PROPYLENE COPOLYMER BOREALIS AG (AT) 2025-06-26 US claimed
US-20250163256-A1 NUCLEATED BIMODAL POLYPROPYLENE BOREALIS AG (AT) 2025-05-22 US claimed
CN-118973917-A Living hinge for alpha-nucleated propylene copolymers 博里利斯股份公司 2024-11-15 CN claimed
CN-118749009-A Nucleated bimodal polypropylene 博里利斯股份公司 2024-10-08 CN claimed
EP-4249388-B1 LIVING HINGE OF AN ALPHA-NUCLEATED PROPYLENE COPOLYMER BOREALIS AG (AT) 2024-06-19 EP claimed
US-20240084149-A1 POLYMER PARTICLES AND RELATED ADDITIVE MANUFACTURING METHODS XEROX CORPORATION (US) 2024-03-14 US claimed
US-11859103-B2 Polymer particles and related additive manufacturing methods XEROX CORPORATION (US) 2024-01-02 US claimed
US-11739202-B2 Bimodal polypropylene random copolymer with improved gamma-irradiation resistance BOREALIS AG (AT) 2023-08-29 US claimed
WO-2023117789-A1 HIGH IMPACT POLYPROPYLENE COMPOSITION SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2023-06-29 WO claimed
WO-2007120147-A1 ARTICLES FROM PLASTICIZED THERMOPLASTIC POLYLEFIN COMPOSITIONS EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-10-25 WO claimed
US-20070060508-A1 Binding molecules APLAGEN GMBH (DE) 2007-03-15 US claimed
US-20060189744-A1 Articles from plasticized thermoplastic polyolefin compositions EXXONMOBIL CHEMICAL PATENTS, INC. 2006-08-24 US claimed
JP-2006513980-A 2006-04-27 JP claimed
EP-1527096-A2 BINDING MOLECULES AplaGen GmbH (DE) 2005-05-04 EP claimed
EP-1394180-A1 Synthetic mimetic molecules of physiological binding molecules AplaGen GmbH (DE) 2004-03-03 EP claimed
WO-2004014951-A2 BINDING MOLECULES APLAGEN GMBH (DE) 2004-02-19 WO claimed
JP-2004502669-A 2004-01-29 JP claimed
EP-1353898-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-10-22 EP claimed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060508-A1 Binding molecules CD74, CLTB, CD2BP2 KDM4E 4747/4885ALDH1A1 2322/4885MAPT 4204/4885
US-12534627-B2 Polymer particles and related additive manufacturing methods LSM12, SMC3, LSM8 KDM4E 2471/4885ALDH1A1 4241/4885MAPT 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.